<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药时代 | wechat-feeds</title><link>http://MzI5NzY0NDQyNQ.favicon.privacyhide.com/favicon.ico</link><description>欢迎您走进药时代！这是一个千载难逢的医药研发新时代！我们分享最新的有价值的行业资讯，讲述医药背后感人的故事，举办形式多样、内容丰富的线上线下活动，与朋友们一起学习成长，将新药研发事业进行到底，让新药带给世界更多更大的健康和希望！</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 31 May 2021 18:03:53 +0800</pubDate><image><url>http://MzI5NzY0NDQyNQ.favicon.privacyhide.com/favicon.ico</url><title>药时代 | wechat-feeds</title><link>http://MzI5NzY0NDQyNQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>中国好合伙人｜同筑新药梦，共创大未来！</title><link>https://mp.weixin.qq.com/s/ZFiKwqcrnX0My0xenrKAdA</link><description></description><content:encoded><![CDATA[中国好合伙人｜同筑新药梦，共创大未来！]]></content:encoded><pubDate>Mon, 31 May 2021 17:00:28 +0800</pubDate></item><item><title>NASH专栏｜漫谈NASH - 药物治疗</title><link>https://mp.weixin.qq.com/s/6BFcLxF7T7vNnZKCqp3h8A</link><description></description><content:encoded><![CDATA[NASH专栏｜漫谈NASH - 药物治疗]]></content:encoded><pubDate>Mon, 31 May 2021 17:00:28 +0800</pubDate></item><item><title>全球首个ABL变构抑制剂提交中国临床实验申请</title><link>https://mp.weixin.qq.com/s/KiIw2gTueu-nGS0FkqQtsA</link><description></description><content:encoded><![CDATA[全球首个ABL变构抑制剂提交中国临床实验申请]]></content:encoded><pubDate>Mon, 31 May 2021 17:00:28 +0800</pubDate></item><item><title>迄今最大胶质母细胞瘤“地图”，丁莉团揭示致命脑瘤中起关键作用的生物图谱</title><link>https://mp.weixin.qq.com/s/m8D6XFm4h_T96rDjEIQl7g</link><description></description><content:encoded><![CDATA[迄今最大胶质母细胞瘤“地图”，丁莉团揭示致命脑瘤中起关键作用的生物图谱]]></content:encoded><pubDate>Mon, 31 May 2021 17:00:28 +0800</pubDate></item><item><title>肾移植受者联合用药对他克莫司影响及其剂量调整策略</title><link>https://mp.weixin.qq.com/s/d3u1bvDRqzrz-vFsMRzHGg</link><description></description><content:encoded><![CDATA[肾移植受者联合用药对他克莫司影响及其剂量调整策略]]></content:encoded><pubDate>Mon, 31 May 2021 17:00:28 +0800</pubDate></item><item><title>口服缓控释制剂的体内外相关性(IVIVC)</title><link>https://mp.weixin.qq.com/s/vzHvDL9f9dPLmRenc3TqdQ</link><description></description><content:encoded><![CDATA[口服缓控释制剂的体内外相关性(IVIVC)]]></content:encoded><pubDate>Mon, 31 May 2021 17:00:28 +0800</pubDate></item><item><title>BPIT重磅报告丨吴朝晖：干细胞制剂的质量的关键在于设计和生产</title><link>https://mp.weixin.qq.com/s/3o0mMoAEvqSOdMDfA4cKLA</link><description></description><content:encoded><![CDATA[BPIT重磅报告丨吴朝晖：干细胞制剂的质量的关键在于设计和生产]]></content:encoded><pubDate>Mon, 31 May 2021 17:00:28 +0800</pubDate></item><item><title>一项随机对照试验证实：不打针，不吃药，8周内年轻3岁不是梦！</title><link>https://mp.weixin.qq.com/s/kwcYVg8PXR2UG9AgPA31sQ</link><description></description><content:encoded><![CDATA[一项随机对照试验证实：不打针，不吃药，8周内年轻3岁不是梦！]]></content:encoded><pubDate>Mon, 31 May 2021 17:00:28 +0800</pubDate></item><item><title>First-in-Class！与药时代大咖共进午餐，您准备好了吗？</title><link>https://mp.weixin.qq.com/s/DCyJinAZc5Zh1exUed4q4w</link><description></description><content:encoded><![CDATA[First-in-Class！与药时代大咖共进午餐，您准备好了吗？]]></content:encoded><pubDate>Sun, 30 May 2021 17:00:30 +0800</pubDate></item><item><title>率先突围，百时美施贵宝S1PR调节剂ozanimod获批治疗溃疡性结肠炎</title><link>https://mp.weixin.qq.com/s/eUXD80hJMZ4GgD2VDlCIXw</link><description></description><content:encoded><![CDATA[率先突围，百时美施贵宝S1PR调节剂ozanimod获批治疗溃疡性结肠炎]]></content:encoded><pubDate>Sun, 30 May 2021 17:00:30 +0800</pubDate></item><item><title>Viruses：新基因测定法助力新冠药物大洗牌</title><link>https://mp.weixin.qq.com/s/5UB_Crpv6r7GJruQ5hACUg</link><description></description><content:encoded><![CDATA[Viruses：新基因测定法助力新冠药物大洗牌]]></content:encoded><pubDate>Sun, 30 May 2021 17:00:30 +0800</pubDate></item><item><title>老药新用：FDA受理乌地那非新适应症上市申请，已授予优先审评</title><link>https://mp.weixin.qq.com/s/RKBSCDB1bO1uyGsSc7dGgg</link><description></description><content:encoded><![CDATA[老药新用：FDA受理乌地那非新适应症上市申请，已授予优先审评]]></content:encoded><pubDate>Sun, 30 May 2021 17:00:30 +0800</pubDate></item><item><title>【Nature cancer】非小细胞肺癌中EGFR抑制剂耐药的最新进展</title><link>https://mp.weixin.qq.com/s/ekvvJjaAUC3vX4eksNaTBw</link><description></description><content:encoded><![CDATA[【Nature cancer】非小细胞肺癌中EGFR抑制剂耐药的最新进展]]></content:encoded><pubDate>Sun, 30 May 2021 17:00:30 +0800</pubDate></item><item><title>抗体类药物研发生产现状分析</title><link>https://mp.weixin.qq.com/s/psXJcQmVkDuMuUEPz4g2Gw</link><description></description><content:encoded><![CDATA[抗体类药物研发生产现状分析]]></content:encoded><pubDate>Sun, 30 May 2021 17:00:30 +0800</pubDate></item><item><title>重磅！国研自强！国产CAR-T疗法达100%缓解！长期有效！《Blood》最新研究</title><link>https://mp.weixin.qq.com/s/8t9zBxk1FRLe2ObTVsWP_Q</link><description></description><content:encoded><![CDATA[重磅！国研自强！国产CAR-T疗法达100%缓解！长期有效！《Blood》最新研究]]></content:encoded><pubDate>Sun, 30 May 2021 17:00:30 +0800</pubDate></item><item><title>常喝牛奶，容易胖但胆固醇更低？</title><link>https://mp.weixin.qq.com/s/NTK1DkOdcrWtvbVNZAjvyw</link><description></description><content:encoded><![CDATA[常喝牛奶，容易胖但胆固醇更低？]]></content:encoded><pubDate>Sun, 30 May 2021 17:00:30 +0800</pubDate></item><item><title>​众望所归！FDA加速批准安进AMG 510上市｜首款针对KRAS G12C 突变的靶向药物</title><link>https://mp.weixin.qq.com/s/QrOCBuWRGXa3CWsiiqvrZA</link><description></description><content:encoded><![CDATA[​众望所归！FDA加速批准安进AMG 510上市｜首款针对KRAS G12C 突变的靶向药物]]></content:encoded><pubDate>Sat, 29 May 2021 17:09:52 +0800</pubDate></item><item><title>重磅消息扎堆！再鼎医药瑞派替尼商业上市、人福药业1类新药获批、阿斯利康与绿叶又一交易达成、基石药业泰吉华商业化上市。。。</title><link>https://mp.weixin.qq.com/s/mEnIJPIJ_xpwLq54oxJDsQ</link><description></description><content:encoded><![CDATA[重磅消息扎堆！再鼎医药瑞派替尼商业上市、人福药业1类新药获批、阿斯利康与绿叶又一交易达成、基石药业泰吉华商业化上市。。。]]></content:encoded><pubDate>Sat, 29 May 2021 17:09:52 +0800</pubDate></item><item><title>一致性评价Top10品种分析：过评339个，齐鲁一骑红尘，石药、科伦紧跟</title><link>https://mp.weixin.qq.com/s/lrSCOgadb5XfB4lHgMfa7w</link><description></description><content:encoded><![CDATA[一致性评价Top10品种分析：过评339个，齐鲁一骑红尘，石药、科伦紧跟]]></content:encoded><pubDate>Sat, 29 May 2021 17:09:52 +0800</pubDate></item><item><title>高端访谈|荣昌生物房健民：创新药需优化创新环境，提升风险承受力及科研转化率！</title><link>https://mp.weixin.qq.com/s/P444O13ccP174CLjLOGCFA</link><description></description><content:encoded><![CDATA[高端访谈|荣昌生物房健民：创新药需优化创新环境，提升风险承受力及科研转化率！]]></content:encoded><pubDate>Sat, 29 May 2021 17:09:52 +0800</pubDate></item></channel></rss>